NASDAQ:HRMY Harmony Biosciences (HRMY) Stock Price, News & Analysis → [BUY ALERT] Our #1 A.I. Stock for March (From Behind the Markets) (Ad) Free HRMY Stock Alerts $33.58 +0.06 (+0.18%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$32.62▼$33.9850-Day Range$29.93▼$35.0652-Week Range$18.61▼$39.26Volume303,545 shsAverage Volume368,634 shsMarket Capitalization$1.91 billionP/E Ratio15.84Dividend YieldN/APrice Target$41.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Harmony Biosciences alerts: Email Address Harmony Biosciences MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside22.1% Upside$41.00 Price TargetShort InterestBearish19.81% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.15Based on 7 Articles This WeekInsider TradingSelling Shares$389,536 Sold Last QuarterProj. Earnings Growth31.33%From $3.00 to $3.94 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.41 out of 5 starsMedical Sector123rd out of 938 stocksPharmaceutical Preparations Industry46th out of 422 stocks 3.3 Analyst's Opinion Consensus RatingHarmony Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 6 buy ratings, no hold ratings, and 2 sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $41.00, Harmony Biosciences has a forecasted upside of 22.1% from its current price of $33.58.Amount of Analyst CoverageHarmony Biosciences has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 1.0 Short Interest Percentage of Shares Shorted19.81% of the float of Harmony Biosciences has been sold short.Short Interest Ratio / Days to CoverHarmony Biosciences has a short interest ratio ("days to cover") of 16.9, which indicates bearish sentiment.Change versus previous monthShort interest in Harmony Biosciences has recently decreased by 3.18%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldHarmony Biosciences does not currently pay a dividend.Dividend GrowthHarmony Biosciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for HRMY. Previous Next 2.9 News and Social Media Coverage News SentimentHarmony Biosciences has a news sentiment score of 1.15. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Harmony Biosciences this week, compared to 4 articles on an average week.Search InterestOnly 6 people have searched for HRMY on MarketBeat in the last 30 days. This is a decrease of -45% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Harmony Biosciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -75% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Harmony Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $389,536.00 in company stock.Percentage Held by Insiders28.40% of the stock of Harmony Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions86.23% of the stock of Harmony Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 4.4 Earnings and Valuation Earnings GrowthEarnings for Harmony Biosciences are expected to grow by 31.33% in the coming year, from $3.00 to $3.94 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Harmony Biosciences is 15.84, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 147.65.Price to Earnings Ratio vs. SectorThe P/E ratio of Harmony Biosciences is 15.84, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 276.03.Price to Earnings Growth RatioHarmony Biosciences has a PEG Ratio of 0.45. PEG Ratios below 1 indicate that a company could be undervalued.Price to Book Value per Share RatioHarmony Biosciences has a P/B Ratio of 4.21. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the Markets[BUY ALERT] Our #1 A.I. Stock for MarchIt's the one AI stock nobody is talking about. Cathy Wood just bought 11 million shares of it.Get the name of the stock here - before it takes off >>> About Harmony Biosciences Stock (NASDAQ:HRMY)Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.Read More HRMY Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart HRMY Stock News HeadlinesMarch 19, 2024 | insidertrades.comHarmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Insider Jeffrey Dierks Sells 11,979 SharesMarch 28, 2024 | markets.businessinsider.comEvaluating Harmony Biosciences: Insights From 8 Financial AnalystsMarch 29, 2024 | Behind the Markets (Ad)[BUY ALERT] Our #1 A.I. Stock for MarchIt's the one AI stock nobody is talking about. Cathy Wood just bought 11 million shares of it.March 28, 2024 | americanbankingnews.comHarmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Receives Average Rating of "Moderate Buy" from BrokeragesMarch 26, 2024 | finance.yahoo.comHARMONY BIOSCIENCES TO PARTICIPATE IN 23RD ANNUAL NEEDHAM VIRTUAL HEALTHCARE CONFERENCEMarch 19, 2024 | benzinga.comInsider Activity Update: Jeffrey Dierks Executes Options Exercise, Resulting In $279K At Harmony BiosciencesMarch 19, 2024 | finance.yahoo.comHarmony Biosciences Holdings Inc's Chief Commercial Officer Sells Company SharesMarch 17, 2024 | finance.yahoo.comHRMY Oct 2024 35.000 putMarch 29, 2024 | Behind the Markets (Ad)[BUY ALERT] Our #1 A.I. Stock for MarchIt's the one AI stock nobody is talking about. Cathy Wood just bought 11 million shares of it.March 16, 2024 | finance.yahoo.comHRMY Apr 2024 30.000 putMarch 16, 2024 | finance.yahoo.comHRMY Jul 2024 30.000 putMarch 6, 2024 | morningstar.comHarmony Biosciences Holdings Inc Ordinary Shares HRMYMarch 6, 2024 | msn.comHarmony Biosciences Set to Share Insights at Upcoming Investor ConferencesFebruary 28, 2024 | prnewswire.comHARMONY BIOSCIENCES TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCESFebruary 26, 2024 | msn.comHarmony Biosciences' Narcolepsy Drug for Children Gets FDA Priority ReviewFebruary 24, 2024 | msn.comHarmony Biosciences Holdings (HRMY) Price Target Increased by 6.29% to 43.10February 22, 2024 | finance.yahoo.comHarmony Biosciences Holdings Inc (HRMY) Reports Robust Revenue Growth in Q4 and Full Year 2023February 22, 2024 | finance.yahoo.comHarmony Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Business UpdatesFebruary 22, 2024 | globenewswire.comHarmony Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Business UpdatesFebruary 21, 2024 | markets.businessinsider.comHarmony Biosciences Receives FDA Priority Review For WakixFebruary 21, 2024 | msn.comHarmony Biosciences Q4 2023 Earnings PreviewFebruary 21, 2024 | finance.yahoo.comU.S. FOOD AND DRUG ADMINISTRATION GRANTS PRIORITY REVIEW TO HARMONY BIOSCIENCES' APPLICATION FOR WAKIX® (PITOLISANT) IN PEDIATRIC NARCOLEPSYFebruary 21, 2024 | prnewswire.comU.S. FOOD AND DRUG ADMINISTRATION GRANTS PRIORITY REVIEW TO HARMONY BIOSCIENCES' APPLICATION FOR WAKIX® (PITOLISANT) IN PEDIATRIC NARCOLEPSYFebruary 20, 2024 | msn.comHarmony gets FDA orphan drug status for Prader-Willi treatmentFebruary 20, 2024 | markets.businessinsider.comHarmony Biosciences Receives FDA's Orphan Drug Designation For Pitolisant In Prader-Willi SyndromeFebruary 20, 2024 | finance.yahoo.comHARMONY BIOSCIENCES RECEIVES U.S. FOOD AND DRUG ADMINISTRATION ORPHAN DRUG DESIGNATION FOR PITOLISANT IN PRADER-WILLI SYNDROMEFebruary 20, 2024 | prnewswire.comHARMONY BIOSCIENCES RECEIVES U.S. FOOD AND DRUG ADMINISTRATION ORPHAN DRUG DESIGNATION FOR PITOLISANT IN PRADER-WILLI SYNDROMESee More Headlines Receive HRMY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Harmony Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/22/2024Today3/28/2024Next Earnings (Estimated)5/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:HRMY CUSIPN/A CIK1802665 Webwww.harmonybiosciences.com Phone484-539-9800FaxN/AEmployees246Year FoundedN/APrice Target and Rating Average Stock Price Target$41.00 High Stock Price Target$59.00 Low Stock Price Target$27.00 Potential Upside/Downside+22.1%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)$2.12 Trailing P/E Ratio15.84 Forward P/E Ratio11.19 P/E Growth0.45Net Income$128.85 million Net Margins22.16% Pretax Margin29.79% Return on Equity27.49% Return on Assets16.83% Debt Debt-to-Equity Ratio0.38 Current Ratio2.75 Quick Ratio2.72 Sales & Book Value Annual Sales$582.02 million Price / Sales3.28 Cash Flow$2.73 per share Price / Cash Flow12.28 Book Value$7.97 per share Price / Book4.21Miscellaneous Outstanding Shares56,770,000Free Float40,647,000Market Cap$1.91 billion OptionableOptionable Beta0.72 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesMr. Jeffrey S. Aronin (Age 56)Founder & Non-Executive Chairman Comp: $19.6kDr. Jeffrey M. Dayno M.D. (Age 67)President, CEO & Director Comp: $762.15kMr. Jeffrey Dierks M.B.A. (Age 52)Executive VP & Chief Commercial Officer Comp: $662.1kMr. Andrew Serafin J.D. (Age 49)M.B.A., Executive VP & Chief Strategy Officer Comp: $605.42kMr. David BradshawHead of Technical OperationsLuis SanayHead of Investor RelationsMr. Christian UlrichGeneral Counsel & Corporate SecretaryMs. Tricia GloverChief Compliance OfficerMs. Audrey Murphy SPHRHead of Human ResourcesMs. Cate McCanlessHead of Corporate Affairs & Public PolicyMore ExecutivesKey CompetitorsSyndax PharmaceuticalsNASDAQ:SNDXGeronNASDAQ:GERNAmneal PharmaceuticalsNASDAQ:AMRXSchrödingerNASDAQ:SDGRCatalyst PharmaceuticalsNASDAQ:CPRXView All CompetitorsInsiders & InstitutionsJeffrey DierksSold 11,979 sharesTotal: $383,328.00 ($32.00/share)Vanguard Group Inc.Sold 9,388 shares on 3/11/2024Ownership: 6.473%Jeffrey DierksSold 194 sharesTotal: $6,208.00 ($32.00/share)Wellington Management Group LLPBought 39,436 shares on 3/5/2024Ownership: 0.069%Goldman Sachs Group Inc.Bought 69,142 shares on 3/1/2024Ownership: 0.478%View All Insider TransactionsView All Institutional Transactions HRMY Stock Analysis - Frequently Asked Questions Should I buy or sell Harmony Biosciences stock right now? 8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Harmony Biosciences in the last twelve months. There are currently 2 sell ratings and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" HRMY shares. View HRMY analyst ratings or view top-rated stocks. What is Harmony Biosciences' stock price target for 2024? 8 equities research analysts have issued 12 month target prices for Harmony Biosciences' shares. Their HRMY share price targets range from $27.00 to $59.00. On average, they anticipate the company's stock price to reach $41.00 in the next year. This suggests a possible upside of 22.1% from the stock's current price. View analysts price targets for HRMY or view top-rated stocks among Wall Street analysts. How have HRMY shares performed in 2024? Harmony Biosciences' stock was trading at $32.30 on January 1st, 2024. Since then, HRMY stock has increased by 4.0% and is now trading at $33.58. View the best growth stocks for 2024 here. When is Harmony Biosciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 7th 2024. View our HRMY earnings forecast. How were Harmony Biosciences' earnings last quarter? Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) posted its quarterly earnings results on Thursday, February, 22nd. The company reported $0.45 EPS for the quarter, missing analysts' consensus estimates of $0.74 by $0.29. The business had revenue of $168.40 million for the quarter, compared to analysts' expectations of $168.90 million. Harmony Biosciences had a net margin of 22.16% and a trailing twelve-month return on equity of 27.49%. The company's revenue for the quarter was up 31.3% on a year-over-year basis. During the same period last year, the firm earned $1.01 EPS. What ETFs hold Harmony Biosciences' stock? ETFs with the largest weight of Harmony Biosciences (NASDAQ:HRMY) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN), SPDR S&P Pharmaceuticals ETF (XPH), Virtus LifeSci Biotech Products ETF (BBP), Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL), Invesco S&P SmallCap Health Care ETF (PSCH) and First Trust Nasdaq Pharmaceuticals ETF (FTXH).iShares U.S. Pharmaceuticals ETF (IHE). What guidance has Harmony Biosciences issued on next quarter's earnings? Harmony Biosciences issued an update on its FY 2024 earnings guidance on Tuesday, February, 27th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $700.0 million-$720.0 million, compared to the consensus revenue estimate of $712.3 million. What other stocks do shareholders of Harmony Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Harmony Biosciences investors own include Advance Auto Parts (AAP), Advanced Micro Devices (AMD), Boeing (BA), Berry Global Group (BERY), Bunge Global (BG), Carrier Global (CARR), Commercial Metals (CMC), Canadian Solar (CSIQ), Deere & Company (DE) and Eastman Chemical (EMN). When did Harmony Biosciences IPO? Harmony Biosciences (HRMY) raised $101 million in an IPO on Wednesday, August 19th 2020. The company issued 4,700,000 shares at $20.00-$23.00 per share. Goldman Sachs, Jefferies and Piper Sandler acted as the underwriters for the IPO. Who are Harmony Biosciences' major shareholders? Harmony Biosciences' stock is owned by many different institutional and retail investors. Top institutional investors include Vanguard Group Inc. (6.27%), Vanguard Group Inc. (6.47%), Pacer Advisors Inc. (2.09%), Dimensional Fund Advisors LP (1.26%), abrdn plc (0.91%) and Federated Hermes Inc. (0.90%). Insiders that own company stock include Andreas Wicki, Jack Nielsen, Jeffrey Dierks, Jeffrey M Dayno, Jeffrey M Dayno, John C Jacobs and John C Jacobs. View institutional ownership trends. How do I buy shares of Harmony Biosciences? Shares of HRMY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:HRMY) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryAI healthcare stock poised for 36,996% growth?Behind the MarketsOnly a fool would buy Nvidia today… Porter & CompanyBill Gates is all about this tiny $2 stockTimothy Sykes Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Harmony Biosciences Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.